The 2019 ADA/EASD consensus recommends SGLT-2 inhibitors on top of metformin in people with diabetes and HF (especially HFrEF) in order to reduce HHF, MACE, and CV death [138]. This evidence concerns the gene SLC5A2 and diabetes mellitus.